OTC: AAQL

Antiaging Quantum Living Inc.

CIK 0001672571 · SIC 7331 · Direct Mail Advertising Services

Micro Revenue $1M Assets $3M as of Aug 23, 2026

Antiaging Quantum Living Inc., previously known as Achison Inc., (the “Company”) is a New York corporation formed on December 29, 2014. Our current principal executive office is 135-27 38th Ave #388, Flushing, NY 11354, New York. Tel: 929-990-3255. About this business →

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (PURR 10-K) is open in full — no account needed.

10-Q Filed Aug 14, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

10-K Filed Jul 14, 2026 · Period ending Mar 31, 2026

Summary not yet generated.

Partner

Trade AAQL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

10-Q Filed Feb 13, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

424B3 Filed Dec 22, 2025

Summary not yet generated.

S-1 Filed Dec 12, 2025

Summary not yet generated.

10-Q Filed Nov 12, 2025 · Period ending Sep 30, 2025

Summary not yet generated.

10-Q Filed Aug 14, 2025 · Period ending Jun 30, 2025

Summary not yet generated.

10-K Filed Jul 2, 2025 · Period ending Mar 31, 2025

Summary not yet generated.

8-K Filed Jul 31, 2024 · Period ending Jul 25, 2024

Summary not yet generated.

8-K Filed Jun 21, 2024 · Period ending Jun 6, 2024

Summary not yet generated.

8-K Filed Jan 3, 2024 · Period ending Jan 3, 2024

Summary not yet generated.

Latest financial statements

From 10-Q filed Aug 14, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

Description Three months ended June 30, 2026 Three months ended June 30, 2025
Revenues, net 730,117 291,438
Cost of revenues 417,227 56,706
Gross profit 312,890 234,732
Operating expenses:
Selling and marketing expenses 335,484 12,612
General and administrative expenses 300,482 360,323
Total operating expenses 635,966 372,935
Loss from operations (323,076) (138,203)
Other income:
Interest income 39 21
Other income 4,528 10,810
Total other income 4,567 10,831
Loss before income tax (318,509) (127,372)
Income tax expense - 6,000
Net loss (318,509) (133,372)
Weighted average shares outstanding
Basic and diluted 34,275,340 29,995,000
Loss per share
Basic and diluted (0.0093) (0.0045)
Comprehensive loss:
Net loss (318,509) (133,372)
Other comprehensive loss:
Foreign currency translation adjustment (1,088) (7,937)
Total comprehensive loss (319,597) (141,309)

Condensed Consolidated Balance Sheets

Description June 30, 2026 (Unaudited) March 31, 2026 (Audited)
ASSETS
Current Assets
Cash and cash equivalents 608,100 503,486
Accounts receivable, net 744,840 30,000
Inventories, net 342,386 219,036
Advances to suppliers 160,473 231,523
Other receivables and current assets 453,697 229,937
Total Current Assets 2,309,496 1,213,982
Non-Current Assets
Property and equipment, net 138,341 148,215
Intangible assets, net 12,650 12,806
Operating lease right of use asset, net 799,480 347,682
Total Non-Current Assets 950,471 508,703
Total Assets 3,259,967 1,722,685
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued expenses 402,632 389,582
Accounts payable related party 24,324 -
Other payables 802,791 153,364
Due to related parties 980,000 980,000
Taxes payable 591 1,297
Contract liabilities 523,933 97,605
Operating lease liabilities current portion 52,635 51,172
Total Current Liabilities 2,786,906 1,673,020
Non-Current Liabilities
Operating lease liabilities non-current 481,071 319,621
Long term loans payable 987,458 405,915
Total Non-Current Liabilities 1,468,529 725,536
Total Liabilities 4,255,435 2,398,556
Commitments and Contingencies - -
Shareholders’ Equity
Class A Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; 34,275,340 and 29,995,000 shares issued and outstanding at June 30, 2026 and March 31, 2026 30,423 30,423
Class B Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and March 31, 2026 -
Class C Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and March 31, 2026 - -
Class D Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and March 31, 2026 - -
Class E Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and March 31, 2026 - -
Additional paid-in capital 1,527,204 1,527,204
Accumulated deficit (2,565,867) (2,247,358)
Accumulated other comprehensive (loss) income 12,772 13,860
Total Shareholders’ Deficit (995,468) (675,871)
Total Liabilities and Shareholders’ Deficit 3,259,967 1,722,685

Condensed Consolidated Statements of Cash Flows (Unaudited)

Description Three months ended June 30, 2026 Three months ended June 30, 2025
Cash flows from operating activities
Net loss (318,509) (133,372)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense 10,291 35,782
Amortization of operating lease ROU assets 54,176 98,337
Write-off assets - 3,934
Changes in assets and liabilities
Increase in accounts receivable (712,859) (187,547)
Increase in inventories (121,528) -
Decrease in advances to suppliers 74,686 16,386
Increase in prepaid expenses (193,785) -
(Increase) decrease in other receivables and current assets (7,656) 1,282
Increase in customer advances 30,731 -
(Decrease) increase in accounts payable (63,763) 14,934
Increase in bank overdraft 24,253 -
Increase (decrease) in accrued expenses and other payables 700,050 (22,655)
Increase in taxes payable - 6,177
Increase in contract liabilities 394,453 -
Decrease in operating lease liabilities (342,224) (18,000)
Net cash used in operating activities (471,684) (184,742)
Cash flows from investing activities
Purchase of fixed assets - (1,089)
Net cash used in investing activities - (1,089)
Cash flows from financing activities
Proceeds from borrowings 573,126 -
Proceeds from related party advances - 220,000
Net cash provided by financing activities 573,126 220,000
Net increase of cash and cash equivalents 101,442 34,169
Effect of foreign currency translation on cash and cash equivalents 3,172 1,007
Cash and cash equivalents beginning 503,486 370,549
Cash and cash equivalents ending 608,100 405,725
Supplementary cash flow information:
Interest paid - -
Income taxes paid - -
Non-cash financing and investing activities:
Recognized ROU assets through lease liabilities 504,630 -

Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

About Antiaging Quantum Living Inc.

Source: Item 1 (Business) from the 10-K filed July 14, 2026. Description as filed by the company with the SEC.

Item
1. Business

History
and Overview

Antiaging
Quantum Living Inc., previously known as Achison Inc., (the “Company”) is a New York corporation formed on December 29, 2014.
Our current principal executive office is 135-27 38th Ave #388, Flushing, NY 11354, New York. Tel: 929-990-3255.

On
July 1, 2019 Lansdale Inc, the principal stockholder of the Company (“Seller”) and controlled by the Company’s prior
President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc, (the “Buyer”),
pursuant to which, among other things, Seller agreed to sell to the Buyer, and the Buyer agreed to purchase from Seller, a total of 9,000,000
shares of Class A Common Stock of the Company of record and beneficially by Seller. The Purchased Shares represented approximately 90%
of the Company’s issued and outstanding shares of Class A Common Stock, resulting in a change of the control of the Company. Mr.
Dingshan Zhang was appointed as the President and CEO of the Company at the same date.

3

Prior
to the change of the management team, the Company was engaging in holding or trading securities in the US market, trading spot silver
in Singapore’s market as well as to trade whisky in the UK market. The Company has changed its focus to operate online advertising
business through www.dazhong368.com (the “Website”) in the New York area.

The
Website was established by Mr. Zhang in 2014 which is mainly focused on customers in the Greater New York area. The Website advertises
different markets for professional individuals or companies including real estate, services, accounting, legal and so forth. We charge
certain fees from these advertisements posted on our Website. The Company expects to generate revenue from the online advertising business
and we also seek other profitable business at the same time.

Read full description ↓

On
March 21, 2023, Barry Wan entered into a stock purchase agreement acquiring control of 29,215,000 restricted shares of common stock of
the Company, representing approximately 97.4% of the Company’s total issued and outstanding common stock from Dazhong 368 Inc and
Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director,
Dingshan Zhang (the “transaction”).

On
April 10, 2023, during the closing of the transaction, Barry Wan assigned all his shares to New Lite Ventures LLC (A.K.A. “New
Living Ventures LLC”, “LLC”), a Delaware Limited Liability Company, with which Barry Wan is the sole member. The foregoing
transaction resulted in a change of control of the Company, with LLC 97.4% of the Company’s outstanding Common Stock. Both before
and after the transactions, the Company had 29,995,000 shares of its common stock outstanding.

In
connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April
10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and
Director. On June 16, 2023, Mr. Barry Wan was approved by Directors Resolution to act as the new Chief Executive Officer, Chief Financial
Officer, Treasurer, Secretary, and Chairman of the Board of Directors after Ms. Jing Wan resigned. The Company was renamed as Antiaging
Quantum Living Inc. on June 14, 2023 by the new management. Along with the name change, the ticker symbol of the Company was modified
to “AAQL”. The Company plans to continue its existing operations through its website at www.dazhong368.com, which,
since 2014, has provided online advertising to different individuals or companies operating in real estate, accounting, legal and other
professional services in the New York City area. Its revenues are generated from advertising fees.

On
October 4, 2023, the Board of Directors of the Company approved the appointment of PWN LLP to be the new independent registered public
accounting firm, as a result of the competitive selection process to determine the independent registered public accounting firm for
the financial period ending September 30, 2023. The action effectively dismissed Simon & Edward, LLP as the Company’s independent
registered public accounting firm as of October 4, 2023

On
December 29, 2023, the Board of Directors of the Company adopted a resolution to expand its operations into the global market, specifically
targeting the Asia-Pacific and Chinese markets. In line with this expansion, the Company established multiple business entities as follows:
AAQL Inc. (“BVI Holding”), a British Virgin Islands Company wholly owned by the Company, AAQL HK Limited (“Hong Kong
Holding”), a wholly-owned subsidiary of BVI Holding, Antiaging Doctor Hangzhou Holding LTD (“Dao Ling Doctor Hangzhou”),
a wholly-owned subsidiary of Hong Kong Holding, Dao Ling Doctor (Zhejiang) Health Management Limited (“Dao Ling Doctor Zhejiang”),
a wholly-owned subsidiary of Dao Ling Doctor Hangzhou, and Dao Ling Doctor (Huzhou) Health Management Limited ( “Dao Ling Doctor
Huzhou”), a wholly-owned subsidiary of Dao Ling Doctor Hangzhou. Consequently, this transition eventually shifted the Company from
being categorized as a shell company under 17 CFR § 240.12b-2 to an entity actively conducting business operations through its subsidiaries.

Dao
Ling Doctor Zhejiang’s primary business involves providing professional technical development and maintenance services to distributors
of the “Dao Ling Doctor” brand, and collecting technical service fees.

Dao
Ling Doctor Huzhou’s primary business involves providing health consulting services (excluding diagnosis and treatment services),
network and information security software development and big data services, and other services.

On
June 6, 2024, the holders of a majority of the issued and outstanding voting securities of the Company approved, by written consent,
an amendment to its Certificate of Incorporation of the Company to increase in the number of authorized shares of common stock of the
Company from thirty million (30,000,000) shares of common stock, par value $0.001 per share, to six billion (6,000,000,000) shares of
common stock, par value $0.00001 per share (the “Authorized Capital Increase”). Upon the effectiveness of the Authorized
Capital Increase, the shares of common stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares,
1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares.

On
June 6, 2024, the Certificate of Amendment to the Certificate of Incorporation was filed with New York State Department effectuating
the Authorized Capital Increase.

Products
and Services

Our
current services will focus on website development, maintenance and online business advertisement. Meanwhile, we will also search for
different business opportunities to be acquired by the Company.

We
will continue to improve our online platform in order to expand our customer base. The potential customer resource of our online advertising
platform will be mainly from professional individuals and small companies that will use our platform to promote their services or products
to their end-users.

4

Strategy

Our
strategy is to target the small to medium-sized companies as well as the professional individuals that will use our Website to promote
their products or services. Except to build up a customized ID card introduction for each of our customers, we will also help our customers
to maintain their content information posted under their ID card introduction. We hope this one-stop service will better serve our potential
customers.

Competitive
Conditions

The
online advertising industry is highly competitive, rapidly evolving and subject to constant technological change and intense marketing
by providers with similar products and services.

A
few of our competitors have substantially greater financial, technical and marketing resources, larger customer bases, longer operating
histories, greater name recognition and more established relationships in the industry than we have. As a result, certain of these competitors
may be able to adopt more aggressive pricing policies that could hinder our ability to market our services. We believe that our key competitive
advantages are our ability to deliver reliable, high quality service in a cost-effective manner. We cannot provide assurances, however,
that these advantages will enable us to succeed against comparable service offerings from our competitors